NCT01443650View on ClinicalTrials.gov

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Hypercholesterolemia
Interventions
DRUG

alirocumab SAR236553 (REGN727)

Pharmaceutical form:solution Route of administration: subcutaneous

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY